Febrile ulceronecrotic Mucha-Habermann disease in adult patient successfully treated with systemic corticosteroid

Doença de Mucha-Habermann úlceronecrótica febril em adulto com boa resposta à corticoterapia oral

Abstract: The Febrile Ulceronecrotic Mucha-Habermann (FUMHD) disease is a rare variant of pityriasis lichenoides et varioliformis acuta (PLEVA). Its etiology still remains unknown and it is characterized by a sudden onset of ulceronecrotic skin lesions associated with systemic symptoms. It is reported here the case of a male patient with a sudden and acute evolution of macules and papules, ulceronecrotic and vesicle-bullous lesions associated with systemic symptoms. The patient was treated with prednisone 0,5 mg/kg/day with a dramatic response. The FUMHD is a severe variant of PLEVA and its diagnosis is clinical and histopathological. Many treatments such as methotrexate, corticosteroids and PUVA have been described. However, none of them has been settled.

Keywords: Adrenal cortex hormones; Pityriasis lichenoides; Vasculitis

INTRODUCTION

The Febrile Ulceronecrotic Mucha-Habermann (FUMHD) disease is a rare variant of pityriasis lichenoides et varioliformis acuta (PLEVA) with only 39 cases described in the medical literature up to this moment. Its etiology is uncertain and it is characterized by the occurrence of ulceronecrotic lesions, associated with high fever and systemic symptoms. In adults, besides being a more severe condition, there is also a malignant potential that can be related to the clonality of T cells. This case is reported here due to the rarity and seriousness of the disease in adults and also because of the excellent clinical response to treatment with corticosteroids.

CASE REPORT

Male patient, aged 49, presenting generalized erythematous macules and papules for 1 week (Figure 1), attacking palms, soles and mucous, that developed into vesiculobullous and ulceronecrotic lesions, some with central crust. (Figure 2).
Condition was associated with a general malaise, high fever (40 degrees) and myalgia. Laboratorial exams presented hyponatremia, hypocalcemia and lymphopenia. FTAabs, VDRL, herpes 1 and 2 serology, Anti-HIV 1 and 2, were negative. The histopathological exam confirmed the diagnosis and revealed lymphohistiocytic inflammatory infiltrate, with intense aggression of epidermis, edema and vacuolar degeneration of keratinocytes, intense exocytosis, blistering, with evolution to ulcers and vascular congestion, with extravasation of erythrocytes (Figures 3 and 4), compatible with Mucha-Habermann disease. Prednisone (40 mg/day) was used with excellent therapeutic response. The corticosteroid was then gradually reduced until its complete withdrawal and the patient has not presented so far lesion recurrence.

**DISCUSSION**

It is up to V. Mucha the first publication, in 1916, in Germany, of a case of acute papular–squamous eruption named Parakeratosis Variegata (Unna) or Pityriasis Lichenoides Chronica (Neisser-Juliusberg). R. Habermann, in 1925, suggests a new name for it: Pityriasis Lichenoides et Varioliformis Acuta (PLEVA), also known as Mucha-Habermann disease.

The febrile Ulceronecrotic Mucha-Habermann (FUMHD) disease is a severe variant of *pityriasis lichenoides et varioliformis acuta* (PLEVA, which is...
characterized by the sudden appearance of ulceronecrotic lesions, associated with high fever (40 degrees), myalgia, arthralgia, gastrointestinal and central nervous system symptoms, interstitial pneumonitis, lymphocytic miocarditis and even death. In general, its development is limited to weeks or months, and occasionally it evolves into a chronic disease, with exacerbations and remissions. It frequently affects children and young adults, differently from our case which refers to a 49 year-old patient. The prognosis for children is better than for adults, since in adults the condition is more severe and there is a malignant potential that can be related to the clonality of T cells. In this study, the patient presented excellent clinical response to the therapeutics with systemic corticosteroid, contradicting the medical literature. The etiology of the disease remains uncertain as it is not known yet whether PLEVA is a reaction to hypersensitivity to some infectious agents (HIV, streptococcus, toxoplasma, viral agents), a hypersensitivity vasculitis (immuno-mediated) or if it is a genuine lymphoproliferative process that is part of the scope of skin lymphoproliferative disorder diseases of the T-cell. Despite this, the transformation of T-cells in lymphoma is rare and the similarities with lymphomatoid papulosis are still being debated.

The diagnosis is clinical and histopathological. In the laboratory it is observed VHS, PCR and high leukocytes count. In some patients it can be found antibodies against streptolysin A and eosinophilia. As for the patient studied it was observed hyponatremia, hypocalcemia and lymphopenia apart from the results of serology for HIV, syphilis and herpes being negative. Histopathology showed perivascular lymphocytic inflammatory infiltrates, on the superficial dermis, with epidermic exocytosis from remains of lymphocytes and parakeratotic squamae with accumulation of inflammatory cells among the different layers. Differential diagnoses can be made with lymphomatoid papulosis, syphilis, chickenpox, and erythema multiforme.

Various treatments have been proposed. However, none of them was established as the number of reported cases is still small. Yang describes the use of high doses of oral corticosteroids initially to reduce the inflammatory component and followed by oral erythromycin for maintenance. There is a report of a patient treated with pulsetherapy with methylprednisolone 500mg/day, three consecutive days of oral prednisone 40mg/day followed by maintenance therapy with methotrexate (7,5 mg/week). Other works describe the use of isolated methotrexate, PUVA, acyclovir, azithromycin and 4,4 diaminodiphenyl sulfone. The use of oral cyclosporine, with an initial dose of 2,5mg/kg/day and posteriorly 1,25mg/kg/day, also had good result in a 8-year-old patient with FUMHD. A retrospective analysis of 20 cases demonstrated that 6 out of 15 patients had a favorable therapeutic response to prednisolone, in doses higher than 1 mg/kg/day. In the case presented here, the patient was treated with 0,5 mg/kg/day and he remained without lesions, even after the withdrawal of systemic corticosteroid, and without maintenance therapy.

Although the case reported here had a favourable evolution, the FUMHD is a disease that can be fatal in adults and therefore it needs more studies as the best treatment is not still well established due to the small number of cases described.
REFERENCES


MAILING ADDRESS / ENDEREÇO PARA CORRESPONDÊNCIA:
Priscila Wolf Nassif
Rua Piratininga, 159 apto 122 cep 87013-100
Maringá-PR, Brazil
Phone: 44 9922 1072 / 44 3262 1712
Email: priwolf@gmail.com